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Coupling of the NMDA receptor to neuroprotective and
neurodestructive events
Giles E. Hardingham
Centre for Integrative Physiology, University of Edinburgh, Edinburgh, UK, EH8 9XD
Abstract
NMDA receptors are a subtype of ionotropic glutamate receptor with an important role in the
physiology and pathophysiology of central neurons. Inappropriate levels of Ca2+ influx through
the NMDA receptor can contribute to neuronal loss in acute trauma such as ischemia and
traumatic brain injury, as well as certain neurodegenerative diseases such as Huntington’s.
However, normal physiological patterns of NMDA receptor activity can promote neuroprotection
against both apoptotic and excitotoxic insults. As a result, NMDA receptor blockade can promote
neuronal death outright or render them vulnerable to secondary trauma. Thus, responses to NMDA
receptor activity follow a classical hormetic dose-response curve: both too much and too little can
be harmful. There is a growing knowledge of the molecular mechanisms underlying both the
neuroprotective and neurodestructive effects of NMDA receptor activity, as well as the factors that
determine whether an episode of NMDA receptor activity is harmful or beneficial. It is becoming
apparent that oxidative stress plays a role in promoting neuronal death both in response to both
hyper- and hypoactivity of the NMDA receptor. Increased understanding in this field is leading to
the discovery of new therapeutic targets and strategies for excitotoxic disorders, as well as a
growing appreciation of the harmful consequences of NMDA receptor blockade.
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A. Introduction
NMDARs (N-methyl-D-aspartate (NMDA) receptors) are cation-passing channels gated by
the neurotransmitter glutamate. They play a central role in synaptic transmission and in
mediating synaptic plasticity, learning and memory. NMDARs are also present in
oligodendrocytes and astrocytes [1], as well as non neural cells such as osteoclasts [2] and
chondrocytes [3] where their function is less well understood. Structurally they are
heterotetramers, typically containing two glycine-binding NR1 subunits and two glutamate-
binding NR2 subunits. The NR1 subunit is essential for a functional NMDAR, and has
several splice variants that can influence the properties of the channel. In addition, NMDAR
variety is provided by the four different NR2 subunits (NR2A-D) as well as two NR3 genes
(NR3A and NR3B) which can take the place of NR2. The most widely expressed NMDARs
contain the obligate subunit NR1 plus either NR2B or NR2A or a mixture of the two. NR2B
(and NR2D) is expressed at high levels in early developmental stages which decline post-
natally, while NR2A and NR2C expression levels increase [4]. In adults, NR2A is
ubiquitously expressed in the brain, NR2B is mostly restricted to the forebrain, NR2C to the
cerebellum and NR2D is expressed in small numbers of cells in selected brain regions.
However, NR2A and NR2B exist concurrently in the same brain region and participate in
the formation of a heterotrimeric NR1/NR2A/NR2B functional NMDARs [5].
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The NMDAR channel pore is blocked in a voltage-dependent manner by Mg2+. Synaptic
release of glutamate, the main excitatory neurotransmitter in the mammalian CNS (central
nervous system), causes Na+ influx through AMPA receptors in the postsynaptic cell,
resulting in partial membrane depolarisation sufficient to lift the Mg2+ block. The activated
NMDAR is permeable to Na+ but, crucially, also to Ca2+. This Ca2+ mediates most of the
physiological effects of NMDAR activity.
At the synapse, the NMDAR is linked to a large multi-protein complex via the cytoplasmic
C-termini of NR1 and NR2 subunits [6]. This complex facilitates localisation of the receptor
in specific areas, such as the postsynaptic density (PSD), and facilitates connection to a
variety of downstream signalling molecules through which many downstream effects of
NMDAR activation are mediated [5]. The extreme C-termini of NR2 subunits link to a
group of proteins called MAGUKs (Membrane-associated Guanylate Kinases) which
include PSD-95, SAP-102 (synapse-associated protein) and PSD-93. These proteins contain
several PDZ protein interaction domains through which other proteins are connected. This
highly organised structure facilitates signal coupling, by bringing together cytoplasmic
signal-transducing enzymes and cell-surface receptors. Moreover, it can bring Ca2+-
dependent signalling molecules into close proximity with the site of Ca2+ entry at NMDAR.
For example, nNOS, in interacting with PSD-95, is brought close to the NMDAR and can
thus be efficiently activated by NMDAR-mediated Ca2+ influx [7].
NMDARs are essential mediators of many forms of synaptic plasticity and also mediate
aspects of development and synaptic transmission [8, 9]. However, when excessively
activated, NMDARs can cause cell death in many neuropathological scenarios [10, 11].
During an ischemic episode, extracellular glutamate builds up due to synaptic release and
impaired/reversed uptake mechanisms [12, 13] resulting in overactivation of NMDARs [14].
The destructive effects of excessive NMDAR activity are in contrast to the recent findings
that survival of several neuronal types is dependent on physiological synaptic NMDAR
activity [15, 16]. Responses of neurons to glutamate or NMDA follow a bell-shaped curve:
both too much and too little NMDAR activity is potentially harmful [15-17].
B. Clinical trials for stroke with NMDAR antagonists have been
unsuccessful
Despite a large body of evidence from animal studies implicating NMDAR activity in
neuronal loss following ischemia, the many clinical trials of different NMDAR antagonists
for stroke have failed due to poor tolerance and efficacy [15, 18]. The fact that the NMDAR
plays a central role in synaptic plasticity and transmission, and learning and cognition,
accounts for the undesired psychomimetic and CNS-adverse effects of antagonists [18].
However, trial design may have been erring too far on the side of caution in seeking to avoid
psychosis and other CNS-adverse effects, when these side-effects are on-target and not off-
target effects. Other issues cloud a clear assessment of NMDAR antagonists, such as
numbers of patients within the trials and time taken to administrate the drug. With many
large pharmaceutical companies having shied away from NMDAR antagonists, these issues
may not be resolved any time soon.
Nevertheless, the growing body of evidence that physiological synaptic NMDAR activity
exerts a neuroprotective effect has led to suggestions that it may play a role in promoting
recovery and preventing delayed neuronal loss in the penumbra [15, 19]. Thus, global
NMDAR antagonists may block NMDAR-activated pro-death signals triggered in response
to an ischemic challenge, but also interfere with some recovery or preconditioning processes
in the penumbra. The anti-excitotoxic effects of NMDAR antagonists have never been in
question, but until relatively recently the pro-survival role of the NMDAR was not known
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and so antagonists were not tested in contexts that would expose their harmful effects. A
classic example of the dichotomous nature of NMDA receptor signalling was reported by
the Ikonomidou laboratory who studied the effect of NMDA receptor antagonists as a
protective strategy against traumatic brain injury in young rats [20]. They found that while
NMDAR antagonists CPP and dizocilpine reduced the primary excitotoxic death proximal to
the site of impact, they exacerbated the secondary apoptotic neuronal loss distal to the
impact site. Since secondary apoptotic damage was more severe than primary excitotoxic
damage, the harmful effects of NMDAR antagonism were significant.
In treating disorders associated with pro-death NMDAR signalling, it may be desirable to
block pro-death signalling, without affecting pro-survival signalling or synaptic plasticity.
This will require a thorough understanding of the nature of both survival and death pathways
triggered by the NMDAR, and the factors that make an episode of NMDAR activity
promote survival or death. In this review we will focus on survival and death signalling
through the NMDA receptor, exploring newly emerged concepts and the molecules
involved.
C. Physiological NMDAR activity can be neuroprotective
In contrast to the adverse effects of excessive NMDAR activity, physiological levels of
synaptic NMDAR activity are essential for neuronal survival, since activity blockade was
shown to have deleterious effects. Blockade of NMDAR activity in vivo caused a decrease
in the number of healthy cells, increased density of pyknotic cells and severe deterioration of
the dentate gyrus morphology in first week postnatal rat pups [21]. Elimination of NMDA
receptor activity in vivo causes widespread apoptosis and enhances trauma-induced injury in
developing neurons [20-24]. In the adult CNS, NMDAR blockade exacerbates neuronal loss
when applied after traumatic brain injury and during ongoing neurodegeneration [25], and
prevents the survival of newborn neurons in the adult dentate gyrus [26].
NMDAR signalling to survival has been recapitulated in vitro in neuronal cultures [16, 27],
allowing scientists to study the underlying signalling events. Network disinhibition using the
GABAa receptor antagonist bicuculline enabled selective studies of synaptic NMDAR
activity signalling [28], as opposed to using the unphysiological bath application of
glutamate which would activate synaptic and extrasynaptic NMDARs. Bicuculline blockade
of the tonic inhibition mediated by GABAergic interneurons promotes action potential
bursting which are associated with synaptic NMDAR-dependent Ca2+ transients [28]. Pro-
survival signalling from the NMDA receptor can involve post-translational modifications of
proteins or indeed de novo gene expression. Different signals may have varying importance
under different circumstances [29]. We outline below examples of pro-survival pathways
triggered by synaptic NMDAR activity, and the pro-survival events that they mediate. Fig. 1
illustrates the pathways described.
C i. Activation of the PI3K-Akt pathway
The PI3K (phosphoinositide-3-kinase) - Akt kinase cascade is an important signalling
pathway which contributes to the pro-survival effects of NMDAR activity [29, 30]. It is
activated by NMDAR in many neuronal types, but not in all [27]. Briefly, in response to
extracellular stimuli, PI3K, which can be activated in a Ca2+-dependent manner by Ca2+/
calmodulin [31], catalyses the phosphorylation of the lipid PIP2 (phosphatidylinositol 4,5-
biphosphate) to PIP3 (phosphatidylinositol 3,4,5-triphosphate) in the membrane. The kinase
PDK1 (phosphoinositide-dependent protein kinase) [32] as well as its substrate Akt/PKB
(Protein Kinase B) are recruited to the membrane via their interactions with PIP3 through
their pleckstrin homology (PH) domains. PDK1, along with PDK2 (which is possibly rictor-
mTOR- [33]) then phosphorylates and activates Akt. Akt promotes cell survival and growth
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via phosphorylation and activation or inactivation of its many targets: Akt phosphorylates
and inactivates GSK3β (Glycogen synthase kinase-3 beta; [34]), an event that also
contributes to NMDAR signalling to neuroprotection [35]. Akt mediates further anti-
apoptotic events: it inactivates the pro-apoptotic Bcl-2 family member BAD (Bcl2/Bcl-XL-
antagonist causing cell death) by phosphorylation, thus stopping its interaction with the pro-
survival Bcl-2 family members Bcl-2 and Bcl-XL [36]. The JNK/p38 activator ASK1 can
also be inhibited by Akt phosphorylation [37] and p53 activity is suppressed by Akt, leading
to reduction of Bax expression and of neuronal death [38].
C ii. Suppression of pro-death gene expression
As well as affecting post-translational events that can promote neuroprotection, Akt can also
modify gene expression with neuroprotective effect by promoting the phosphorylation and
subsequent nuclear export of the FOXO (forkhead box O) subfamily of forkhead
transcription factors. FOXOs control the expression of pro-death genes such as Fas ligand
[39] and Bim [40], and these are down-regulated by Akt activation. Akt-dependent FOXO
export has also been observed in the context of NMDAR signalling [35, 41] which triggers
the transcriptional suppression of Thioredoxin-interacting protein (Txnip), a thioredoxin-
inhibiting FOXO1 target gene whose product renders neurons vulnerable to oxidative stress
[41]. Interestingly, we recently found that FOXO1 itself is a FOXO target gene, meaning
that FOXO export triggered by synaptic activity also suppresses FOXO1 gene expression,
likely to lead to long-lasting down-regulation of FOXO target gene expression [42].
Importantly, the transcription of the pro-death transcription factor p53 gene has recently
been shown to be suppressed by synaptic NMDAR activity [43]. P53 is a transcription factor
which regulates a number of pro-apoptotic genes such as Bax and Puma. Knock-down of
P53 expression was found to be neuroprotective, preventing mitochondrial depolarisation in
response to excitotoxic trauma. In a similar vein, we have observed that key components of
the intrinsic apoptosis pathway are transcriptionally repressed by physiologically relevant
synaptic NMDAR activity in vitro and in vivo but via a p53-independent mechanism (GEH,
unpublished results). Thus, activity-dependent suppression of pro-death genes may represent
an important route to neuroprotection, acting in concert with the induction of pro-survival
genes, which is discussed below.
C iii. Nuclear Ca2+ and activation of CREB (cAMP response element-binding protein)
An important mediator of activity-dependent gene expression is the transcription factor
CREB, which binds to the cAMP response element (CRE) [44]. CRE-dependent gene
expression is strongly induced by synaptic NMDAR activity [45]. Ca2+ influx through the
synaptic NMDAR activates the Ras/ERK pathway in the cytoplasm and the nuclear Ca2+/
calmodulin dependent protein kinases, principally CaMKIV. CaMKIV mediates fast CREB
phosphorylation at Ser133, whereas the ERK1/2 pathway promotes CREB phosphorylation
in a slower, more long lasting manner [46, 47]. Ser133 phosphorylation of CREB is
necessary to recruit CBP (CREB-binding protein), a transcriptional cofactor, to CREB. The
transactivation potential of CBP is itself positively regulated by NMDAR activity [48] by a
mechanism involving its phosphorylation on Ser301 by CaMKIV [49]. Gene expression
mediated by CREB can also be mediated by another family of CREB co-activators, the
TORCs (Transducers of Regulated CREB activity, [50, 51] and references therein). TORC2
translocates to the nucleus as a result of the synergistic action of Ca2+ and cAMP signalling,
through calcineurin-mediated TORC2 dephosphorylation and cAMP-mediated inhibition of
the TORC2 kinase SIK2, respectively [50]. In hippocampal neurons TORC1, which is
expressed more abundantly than TORC2, senses the coincidence of Ca2+ and cAMP
signalling and converges this dual signalling to target gene expression by translocating to the
nucleus and potently coactivating CREB [51]. The potential of CREB family-regulated gene
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products to promote neuronal survival was first demonstrated in the context of neurotrophin
signalling [52, 53] and exogenous overexpression [54]. In addition, studies of mice where
CREB and/or CREB family members have been deleted also point to a pro-survival role for
CREB in vivo both pre- and post-natally [55, 56].
CREB-dependent gene expression is causally linked to the long-lasting phase of activity-
dependent neuroprotection against apoptotic insults [29]. This long-lasting phase is
dependent on nuclear Ca2+/calmodulin signalling [29], consistent with the known
requirement for nuclear Ca2+ in CREB activation via CaMKIV [28, 57-59]. Activity-
dependent CRE activation in developing CNS neurons also protects against excitotoxic
trauma [60] which would otherwise result in rapid cell death resembling necrosis.
Expression of the inhibitory CREB family member, ICER, increases in neurons in response
to apoptotic and excitotoxic insults and can promote neuronal death [61]. Thus, CREB
activation by NMDAR signalling may be important in antagonizing the CREB-inhibiting
effects of ICER accumulation.
The importance of NMDAR signalling to CREB in promoting survival in vivo is not as well
established. Activation of CREB in response to transient ischemic episodes is proposed to
contribute to the establishment of ischemic tolerance or preconditioning and may well be
mediated by NMDAR activation [62]. Interestingly, resistance to hypoxic/ischemic death in
different neuronal populations correlates positively with an ability to sustain active
(phosphorylated) CREB [63]: in neurons destined to die CREB is only transiently
phosphorylated [63].
The identity of the CRE-regulated gene(s) responsible for long lasting protection against
apoptosis is beginning to be understood. Genome-wide profiling studies have identified a
large number of CREB target genes, although only a subset of these are induced by CREB-
activating stimuli [64-66]. Furthermore, the identity of the genes within the subset is cell-
type specific and may be stimulus-specific, so is hard to predict in any particular scenario. A
recent study identified two genes that contribute to synaptic NMDAR-dependent
neuroprotection [67]: Btg2, a potentially anti-apoptotic CREB target gene, and Bcl6, a
transcriptional repressor implicated in suppression of p53, also potentially a CREB target.
Both Btg2 and Bcl6 genes confer neuroprotection in the face of apoptotic stimuli like
trophic deprivation and staurosporine treatment, and siRNA-mediated knockdown
demonstrated that their induction was also necessary for synaptic NMDAR-mediated
neuroprotection. While the molecular mechanism of how Btg2 protects is not completely
clear, its expression has recently been shown to render neurons resistant to excitotoxicity-
induced mitochondrial permeability transitions [43] indicating that it may enhance
mitochondrial function, suppress permeability transition, or enhance respiratory capacity.
Another CRE-regulated candidate is the pro-survival neurotrophin BDNF (brain-derived
neurotrophic factor), which is upregulated by NMDAR activity [45] and is known to
promote neuronal survival [27, 68, 69]. NMDAR blockade in vivo reduces BDNF mRNA
expression and in vitro supplementation of neurons with BDNF can rescue them from
NMDAR antagonist-induced neuronal death [70]. Still more protective CREB target genes
are likely to emerge; it is possible that different genes are responsible for neuroprotection
against different types of insult (e.g. apoptotic-like, excitotoxic/necrotic-like, oxidative
stress).
C iv. Synaptic NMDAR activity boosts intrinsic antioxidant defences
Correct redox regulation is essential in all cells, especially in post-mitotic cells such as
neurons where harmful oxidative damage can accumulate. Oxidative damage and stress
occurs when there is an imbalance between production of reactive oxygen species (ROS)
and the cell’s capacity to neutralize them through its intrinsic antioxidant defenses. Neurons
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are particularly susceptible to oxidative damage due to high levels of ROS production
(through respiration and metabolism) and relatively low levels of certain antioxidant
enzymes, particularly catalase [71, 72]. Oxidative damage is implicated in the pathogenesis
of several neurodegenerative diseases as well as acute cerebrovascular disorders[71, 72].
Appropriate redox balance depends on the activity of antioxidant systems. Key among these
are the thiol reducing systems based round thioredoxin and glutathione respectively, which
are important reducers of many oxidative stressors such as peroxides [72, 73]. The principle
source of peroxide is from spontaneous and SOD-catalysed dismutation of superoxide
generated in active mitochondria. However, other sources of peroxides exist, including
products of metabolic pathways involving oxidases/oxygenases (e.g. monoamine oxidase).
We recently showed that the vulnerability of neurons to oxidative death triggered by
exposure to hydrogen peroxide was regulated by synaptic activity acting via NMDA
receptor (NMDAR) signalling ([41], see also commentary [41]). Neurons that were
experiencing (or had recently experienced) higher levels of synaptic NMDAR activity were
far more likely to withstand the oxidative insult than electrically quiet neurons. Neurons
experiencing complete NMDAR blockade were highly vulnerable to peroxide-induced
apoptosis in vitro, and NMDAR blockade in vivo promoted neuronal apoptosis associated
with markers of oxidative damage [41]. It is not completely clear as to why synaptic activity,
acting via Ca2+ signalling, should act to boost antioxidant defences. One possibility is to
protect against increased ROS generation associated with high energy demand. Synaptic
activity and activity-dependent plasticity place high energy demands on a neuron which
must be largely met through oxidative phosphorylation- a process that generates ROS. Thus,
active neurons would ordinarily need to have stronger antioxidant defenses than inactive
ones in order to maintain the correct redox balance.
Investigations into the mechanism behind this revealed that synaptic activity exerted a
number of changes to the thioredoxin-peroxiredoxin system which contributed to the
activity-dependent protection. Synaptic activity enhanced thioredoxin activity and facilitated
the reduction of hyperoxidized peroxiredoxins, an important class of antioxidant enzymes.
These effects were mediated by a coordinated program of gene expression changes ([41],
Fig. 2). Synaptic activity triggered the transcriptional suppression of the thioredoxin
inhibitor Txnip, which, as mentioned above, is a FOXO target gene. Furthermore, enhanced
reduction of hyperoxidized peroxiredoxins was associated with transcriptional induction of
two genes, sulfiredoxin and sestrin 2, whose products are reported to mediate this reaction
[74-76]. The induction of sulfiredoxin was mediated primarily through two AP-1 sites, and
partly via Nrf2 [77], while sestrin2 was activated via two C/EBPβ sites [41]. We did not
address which of sestrin 2 or sulfiredoxin was responsible for reducing peroxiredoxin
hyperoxidation. However, we recently showed that specific induction of sulfiredoxin is
sufficient to prevent peroxiredoxin hyperoxidation in neurons [77], so this is likely to be the
most important, particularly as recent doubt has been cast on the ability of sestrin 2 to
catalyze this reaction [78]. In any case, induction of one (or both) of these genes cooperated
with the suppression of Txnip in boosting antioxidant defenses. The gene expression
changes described above did not account for all the antioxidant effects of synaptic NMDAR
activity. Work is ongoing in the laboratory to investigate another major antioxidant system
which is subject to activity-dependent enhancement-that centred on glutathione (GH,
unpublished observations).
D. NMDAR-mediated cell death
A high and prolonged rise in the extracellular glutamate concentration kills central neurons
[79]. The NMDAR is an important mediator of glutamate-induced excitotoxicity [80] due in
part to its high permeability to Ca2+ and incomplete desensitisation. Pathological activation
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of NMDARs is a major cause of neuronal death following acute excitotoxic trauma such as
brain ischemia, hypoxia and mechanical trauma [10]. Chronic neurodegenerative diseases
may also be associated with excessive NMDAR activation [81, 82]. Strong Ca2+ influx
through the NMDAR triggers a number of intracellular events that lead to neuronal death,
several of which are outlined below and in Fig. 3.
D i. Mitochondrial dysfunction and reactive oxygen/nitrogen species generation
Mitochondrial dysfunction caused by excessive Ca2+ uptake by the mitochondria through
the potential-driven uniporter is a key event in severe excitotoxicity [83, 84]. The
mitochondrial membrane gets depolarised due to this uptake, which inhibits ATP
production, and can even cause depletion of cytosolic ATP due to reversal of the
mitochondrial ATPase. This loss of ATP further limits the ability of the neuron to regulate
intracellular Ca2+ levels. It had been generally accepted that mitochondrial Ca2+ uptake can
also promote ROS production, triggering further mitochondrial damage and delayed Ca2+
deregulation (DCD). However, recent studies have made the case that enhanced ROS
production following a strong excitotoxic insult occurs after DCD, and that most superoxide
production is in any case non-mitochondrial in origin [84, 85]. This does not rule out a role
for oxidative stress, since prior oxidative stress greatly potentiates NMDAR-mediated
toxicity, possibly by reducing mitochondrial ATP supply [86]. Recent evidence for a role for
ROS generation upstream of NMDAR-mediated cell death also focused on a non-
mitochondrial source: NADPH oxidase (NOX). It was reported that activation of NADPH
oxidase is a major source of superoxide production by NMDA receptor overactivation, and
that inhibiting this process was neuroprotective [87].
NMDAR activity-regulated overactivation of the Ca2+-dependent nNOS (neuronal nitric
oxide synthase) also has toxic downstream responses, including mitochondrial dysfunction,
p38 mitogen-activated protein kinase signalling and TRPM (transient receptor potential
melastatin) channel activation [88]. nNOS is bound by its N-terminal PDZ domain to the
post-synaptic density protein PSD-95, which brings it in the proximity of the synaptic
NMDAR that is also bound to PSD-95 via the extreme C-terminal amino acids of its NR2
subunit (its so-called PDZ ligand). nNOS activation leads to Nitric Oxide (NO) production,
which in excess can be toxic both on its own and when combined with other reactive oxygen
species (ROS) such as superoxide to form ONOO− (peroxynitrite). Both NO and ONOO−
can damage cellular components, inhibit mitochondrial respiratory chain enzymes and
promote mitochondrial depolarisation [10]. ONOO− also damages DNA, resulting in single
strand breaks and overactivation of the DNA repair enzyme poly(ADP-ribose) polymerase 1
(PARP-1). Excessive PARP-1 activation can promote neuronal death by depleting cellular
NAD(+) levels and also by triggering the mitochondrial release of apoptosis activating
factor, (AIF) [89, 90]. Another important target of NMDAR signalling to NO production in
excitotoxicity is the cation channel TRPM7 [91]. NMDAR-dependent Ca2+ influx triggers
both NO production via nNOS activation and superoxide production via mechanisms
described above, which combine to form ONOO−, an activator of TRPM7. Since TRPM7
itself passes Ca2+, this results in a positive feedback loop.
D ii. Calpain activation
As well as promoting mitochondrial dysfunction and ROS generation, excessive Ca2+ influx
also causes efflux to be impaired [92, 93]. In neurons, Ca2+ exit from the cell is achieved
through the plasma membrane Ca2+ ATPase pump (PMCA) and Na+/Ca2+ exchangers
(NCXs). Calpains, Ca2+-dependent proteases, are activated by the excessive NMDAR-
mediated Ca2+ influx and cleave a major isoform of the plasma membrane Na+/Ca2+
exchanger (NCX3) impairing its function in cerebellar granule neurons (CGNs) [92]. The
PMCA, which would utilise the energy from ATP hydrolysis to transport Ca2+ across the
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plasma membrane, is inactivated by excitotoxic insults via mechanisms attributed to both
caspases [94] and calpains [93]. Other important calpain targets have recently been revealed:
the metabotropic glutamate receptor mGluR1α [95] and striatal-enriched protein tyrosine
phosphatase (STEP) [96]. NMDAR-dependent, calpain-mediated truncation of the
mGluR1α C-terminal tail does not disrupt coupling to Gq protein activation, but results in
other altered signalling properties of the receptor, including a disruption of PI3K-Akt
signalling, as well as relocating the receptor from dendrites to axons [95]. The functional
result of this truncation is that while wild-type mGluR1α is neuroprotective against
NMDAR excitotoxicity, the truncated form has the opposite effect. NMDAR-mediated
calpain cleavage of STEP led to the sustained activation of the stress-activated pro-death
kinase, p38 (see below). Furthermore, inhibition of STEP cleavage is neuroprotective and
suppresses p38 activation [96].
D iii. Stress-activated protein kinases
Stress-activated protein kinases (SAPKs) are another class of signalling molecules that are
implicated in NMDAR-dependent cell death [97-101]. In CGNs, NMDAR-dependent
excitotoxic death relies upon p38 activation, leading to caspase-independent cell death [97,
99]. In cortical neurons another SAPK family, the c-Jun N-terminal kinases (JNKs)
contribute to NMDAR-dependent cell death in vitro and in vivo as well as p38 [100, 101].
New components of the excitotoxic cell death pathway signalling to p38 are emerging; Rho,
a member of the Rho-family of GTPases, was recently found to contribute to glutamate-
induced p38α-dependent excitotoxic neuronal death [102]. As mentioned above, calpain
cleavage of STEP has also been implicated in p38 activation [96]. In addition, studies in
CGNs and cortical neurons have reported that NMDAR-dependent p38 activation is
dependent on activation of nNOS, which is associated with the NMDA receptor signaling
complex through its association with PSD-95. PSD-95 is itself linked to NMDARs through
interaction with the PDZ ligand of the NR2 subunit. Disruption of NR2 PDZ ligand:PSD-95
interactions that can uncouple the NMDAR from NO production also inhibit p38 activation
[101, 103]. Interestingly, disruption of interactions between the NR2 PDZ ligand and
downstream proteins such as PSD-95 has a remarkably specific effect on the p38 pathway.
NMDAR signalling to pro-survival pathways resulting in activation of Akt or of CREB are
not interfered with [101, 104]. However, the neuroprotection afforded by such as strategy is
imperfect: activation of JNK does not require interactions with PSD-95. Indeed, NMDAR-
induced death via JNK can be reconstituted in non-neuronal cells simply by expressing
functional NMDARs [101]. The mitochondrially targeted antioxidant MitoQ [105] inhibited
NMDAR-activated JNK signalling in cortical neurons, potentially placing ROS generation
upstream of JNK activation [101].
D iv. So many pathways to excitotoxic cell death?
The myriad potential routes to NMDAR-mediated excitotoxicity begs the question as to
which is the most important or dominant mechanism. While cell-type specific differences
may offer a partial explanation, another important consideration is the intensity of the
excitotoxic insult [106]. Extremely high and sustained levels of NMDAR-induced Ca2+
influx will likely cause rapid mitochondrial dysfunction and bioenergetic failure leading to
DCD. On the other hand, incomplete mitochondrial depolarisation or depolarisation of only
a subpopulation of mitochondria may lead to the release of apoptotic factors such as
cytochrome c or AIF, and the activation of apoptotic-like biochemical cascades. Activation
of SAPK-dependent neuronal death may also be associated with more modest excitotoxic
insults near the threshold of toxicity, and take neurons down a more delayed route to death.
Consistent with this, peptide inhibitors of JNK and also of NR2 PDZ ligand interactions are
neuroprotective in excitotoxic models in vitro and in vivo when administered after the insult
[7, 100]. Furthermore, the protective effects of these peptides can be overcome by increasing
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the severity of the toxic insult [101], as can neuroprotection by pharmacological inhibition
of p38 [98]. Another consideration is that studies on apparently different mechanisms of
excitotoxicity may in some cases involve different parts of the same pathway, as illustrated
in Fig. 3. For example, NMDAR-dependent generation of oxidative/nitrosidative stress can
lead on to mitochondrial dysfunction, as well as SAPK and PARP-1 activation. Similarly,
calpain activation acts as a signalling hub for many pro-death events, including p38
activation, disruption of Akt activation, and Ca2+ dyshomeostasis.
E. Oxidative stress plays an important role at both ends of the toxicity
curve
As described in the sections above, blockade of NMDAR activity in vivo promotes neuronal
death associated with oxidative damage [41]. In vitro, NMDAR blockade also renders
neurons vulnerable to oxidative insults through the weakening of antioxidant defenses [41].
At the other end of the toxicity curve, excessive NMDAR activity promotes free radical
production and oxidative stress in vitro and in vivo [87, 88]. Moreover, exogenous oxidative
stress renders neurons particularly vulnerable to NMDAR-induced death [86]. The
involvement of oxidative stress in neuronal loss due to both hyper- and hypo NMDAR
activity raises the possibility that a single intervention aimed at boosting intrinsic
antioxidant defenses could inhibit both forms of neuronal death. This might have be of use
in scenarios where NMDAR activity appears to be having both pro-death and pro-survival
effects, such as the traumatic brain injury model described above [20]. In this instance,
enhancing antioxidant defenses may not only reduce excitotoxic neuronal death, but could
also help mitigate against any harmful effects from co-administered NMDAR antagonists.
F. What determines if an episode of NMDAR activity is neuroprotective or
excitotoxic?
As outlined above, there is a multitude of ways in which NMDAR-dependent Ca2+ influx
can convey the signal downstream to either confer neuroprotection or to trigger programmes
of cell death. A key issue, potentially relevant for designing clinically tolerated drugs against
neurodegenerative conditions caused by excitotoxicity, is how the distinction between what
pathway will be followed is made and what factors affect this. A number of possibilities are
presented here.
F i. Stimulus intensity
The magnitude of activation, be it intensity or duration, is very important in determining the
nature of the response to an episode of NMDAR activity. The classical bell-shaped curve
model of the neuronal response to NMDA or glutamate contends that intermediate, modest/
physiological NMDAR activity levels can promote neuroprotection whereas too low or too
high pathological NMDAR activity promotes cell death. This implies that the effectors of
the pro-survival Ca2+ signalling have a higher affinity (or considerably lower requirements
for Ca2+) than the Ca2+ effectors of death. Therefore the Ca2+ concentration threshold for
activating pro-survival signalling by PI3K, ERK1/2 and CaMKIV must be lower than that
necessary to trigger toxic levels of calpain activation, mitochondrial Ca2+ uptake or NO
production. The key Ca2+-dependent components of the survival pathways are mainly
activated not by Ca2+ directly, but by Ca2+/Calmodulin. Calmodulin is a ubiquitous Ca2+
binding protein which changes conformation when it binds to Ca2+. Ca2+/Calmodulin then
activates a number of downstream signals, including CaMKIV, PI3K and upstream
activators of ERK1/2. As a physiological sensor of elevated Ca2+ levels, calmodulin is
designed to be activated by relatively modest increases in Ca2+. In contrast, central
mediators of NMDAR-dependent cell death, calpains, are not Ca2+/Calmodulin dependent
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but are activated by Ca2+ directly, and require higher levels to be fully induced [107]. The
same can be said of the mitochondrial uniporter, which senses Ca2+ directly and is fully
activated only by high concentrations [108]. Consistent with this, when increasing doses of
NMDA are applied to neurons, only the higher, toxic doses evoke sustained loss of
mitochondrial membrane potential and increases in mitochondrial Ca2+ [35]. Another Ca2+-
dependent promoter of neuronal death, nNOS, is Ca2+/Calmodulin-dependent and indeed
plays important roles in non-pathological signalling processes such as synaptic plasticity.
However, nNOS is also regulated by phosphorylation, and a recent study showed that, in
contrast to non toxic stimuli, high levels of glutamate fail to trigger an inhibitory
phosphorylation event that ensures that nNOS activation is transient [109]. Thus, nNOS
becomes excessively active and contributes to excitotoxic cell death [109].
F ii. NMDAR location
Aside from stimulus intensity, the location of the NMDAR may also profoundly affect the
signals that emanate from the NMDAR. Developing neurons have sizeable pools of
NMDARs at extrasynaptic, as well as synaptic locations, which signal very differently. Ca2+
influx dependent on intense synaptic NMDAR activation is well tolerated by cells whereas
equivalent activation of extrasynaptic NMDARs, either on their own or in the presence of
synaptic NMDAR activation, is less well tolerated, triggering mitochondrial membrane
potential and cell death [45]. The findings from this study were based on hippocampal
neurons and have since been recapitulated independently in cortical neurons [110].
Synaptic vs. extrasynaptic NMDAR regulation of survival and death signals—
Differential synaptic vs. extrasynaptic NMDAR effects extend to several signal pathways.
While synaptic NMDAR activity strongly induces CREB-dependent gene expression,
extrasynaptic NMDARs are coupled to a dominant CREB shut-off pathway that causes
CREB dephosphorylation of its activator site (serine 133)[45]. The developmentally
regulated mechanism of this is discussed elsewhere [111, 112]. In addition to signalling to
CREB, it has also been shown that there is opposing regulation of the ERK1/2 pathway by
synaptic and extrasynaptic NMDARs in hippocampal neurons: synaptic NMDARs activate
the ERK pathway whereas extrasynaptic NMDARs evoke ERK inactivation [113].
Furthermore, only synaptic NMDAR activity is able to promote sustained activation of the
PI3K-Akt pathway [41].
This differential signalling was at apparent odds with the long-standing observation that low
levels of bath-applied NMDA or glutamate are neuroprotective: these stimuli will activate
both synaptic and extrasynaptic NMDA receptors, and yet the pro-death extrasynaptic
NMDA receptor-dependent signal is clearly not dominating. The anti-apoptotic effects of
low doses of NMDA or glutamate have been demonstrated in several neuronal cell types in
vitro, including cerebellar granule cells and hippocampal neurons [114, 115]. Protection
against excitotoxic trauma can also be induced by chronic exposure of neurons to a sub-
toxic dose of glutamate or NMDA [116-118] via a mechanism thought to involve CREB
activation and BDNF synthesis [119, 120]. In addressing this apparent paradox, we found in
neurons exposed to low protecting doses of NMDA, synaptic NMDAR signalling is able to
dominate because synaptic NMDARs are preferentially activated due to the NMDA causing
a dramatic increase in action potential firing [35]. This enhanced firing mediates the
NMDA-induced pro-survival signalling to Akt, ERK1/2 and CREB. In contrast, higher,
toxic doses of NMDA strongly suppress firing rates and hence do not favour synaptic
NMDAR activation [35].
Recently a molecular mechanism was proposed to explain the specific shut-off of CREB by
extrasynaptic NMDAR activity, centred on Jacob, a binding partner of the neuronal Ca2+
binding protein caldendrin [121]. Jacob, when localized in the nucleus, causes CREB
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inactivation and also promotes the loss of synaptic contacts. Jacob contains a nuclear
localisation signal and its nuclear import requires importin α binding. This binding and
nuclear import is competed by caldendrin in a Ca2+-dependent manner. Interestingly it was
reported that synaptic, but not extrasynaptic NMDAR activity promoted caldendrin-
dependent retention of Jacob outside of the nucleus. Extrasynaptic NMDAR activity
promoted the efficient nuclear accumulation of Jacob, with subsequent deleterious effects
[121].
A study involving genome-wide expression analysis has also extended our understanding of
synaptic vs. extrasynaptic signalling [67]. While synaptic NMDARs activated a number of
pro-survival genes (including the aforementioned Btg2 and Bcl6), extrasynaptic NMDARs
failed to do this. Moreover, bath activation of all (synaptic and extrasynaptic) NMDARs
failed to suppress Txnip expression or induce expression of sulfiredoxin or sestrin 2, and
failed to protect neurons from oxidative stress [41]. Not only do extrasynaptic NMDARs fail
to activate pro-survival changes in gene expression, they also couple to expression of a gene
Clca1 which kills neurons [67].
Another very recent study demonstrated that activation of extrasynaptic, but not synaptic
NMDAR activity promoted calpain activation, an important contributor to excitotoxic cell
death. Calpain activation resulted in the cleavage of not only NCX3 (a previously reported
substrate [92]) but also the tyrosine phosphatase STEP [96]. STEP cleavage leads to it being
unable to interact with its normal substrates, including p38, and so leads to sustained
activation of pro-death p38 signalling. A cell-permeable peptide containing the STEP
cleavage site of calpain both blocked cleavage of endogenous STEP and was
neuroprotective in the face of extrasynaptic NMDAR activity [96].
Differential synaptic vs. extrasynaptic NMDAR signalling: when and how?—
Chronic exposure of neurons to glutamate and activation of extrasynaptic NMDARs is
unlikely to occur under normal physiological conditions. However, it may occur under
pathological conditions such as brain injury, or during hypoxic/ischemic (H/I) insults where
neuronal glutamate transporters operate in reverse [12] thereby pumping glutamate out of
the cells into the extracellular medium, building up in the restricted extracellular space.
Reversed uptake by glial cells can also trigger neuronal death through activation of
extrasynaptic NMDARs [122]. Neurons may also be exposed to elevated ambient levels of
glutamate through release from nearby dying cells. Consistent with all this, H/I conditions
cause a NMDAR-dependent CREB inactivation [45] and induction of the Clca1 gene [123].
Given the role of CREB in controlling several pro-survival genes, this shut-off may
contribute to the slowly progressing apoptotic death of neurons (in response to excitotoxic
trauma) that are exposed to toxic levels of glutamate that are insufficient to cause immediate
necrotic cell death [124-126].
The molecular basis for the apparent differences in synaptic/extrasynaptic NMDAR
signalling could be due to differences in the composition of the NMDAR signalling
complexes as opposed to the location of the receptors per se. For example, since caldendrin
is localised to the post-synaptic density, it has been postulated that only trans-synaptic
activation of synaptic NMDARs trigger high enough local Ca2+ transients to promote
caldendrin-mediated retention of Jacob [121]. Differential localisation of a death effector
has also been reported: p38 was found to be enriched at extrasynaptic membranes compared
to synaptic fractions, while other MAP kinases, ERK1/2, were not [96]. Another
contributing factor could be the way in which these distinct pools are activated: brief
saturating activation in the case of trans-synaptic activation of synaptic NMDARs vs.
chronic low level activation of extrasynaptic NMDARs by bath/ambient glutamate.
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Differences in the properties of intracellular Ca2+ transients evoked by these different
stimuli could differentially affect signalling, even if the overall Ca2+ load were similar.
F iii. Does subunit composition matter?
While extrasynaptic NMDARs are preferentially enriched with NR2B-containing NMDARs,
there is little evidence that differences in subunit composition are dramatic enough to
explain the effects observed. However, a recent study has contended that NR2B-containing
NMDARs tend to promote neuronal death, irrespective of location (synaptic or
extrasynaptic) while NR2A-containing NMDARs promote survival [127]. The cytoplasmic
c-terminal tails of NR2A and NR2B are large, show considerable sequence divergence and
have been reported to differentially associate with signalling molecules [128], offering scope
for subunit-specific routes to survival/death. The investigation of subunit-specific
differences in NMDAR signalling is hampered by the lack of a NR2A-specific antagonist
that is sufficiently selective to discriminate in the physiological scenario of trans-synaptic
stimulation [129, 130]. The antagonist NVP-AAM077 has some selectivity for NR2A-
containing NMDARs but studies disagree as to the degree of selectivity, possibly because of
some laboratories studying rodent NMDARs and others human NMDARs expressed in
oocytes [130, 131]. However, it is likely that the difference in the equilibrium constants
(NR2A vs. NR2B) is not sufficient to discriminate between NR2A-containing or NR2B-
containing NMDA receptors being trans-synaptically activated [130]. Moreover, NR2A-
NMDARs have been shown to be capable of mediating excitotoxicity [132], and NR2B-
NMDARs have been shown to be capable of mediating both pro-survival and pro-death
signalling, depending on the stimulation paradigm [133]. As such, the issue of whether the
NR2 subunit influences whether an NMDAR signals to survival or death (controlling for the
amount of Ca2+ passed) remains unresolved.
G. Concluding remarks and future perspectives
The pro-survival role of synaptic NMDARs under physiological conditions and especially
during CNS development, points to the potential dangers of NMDAR antagonism during
this period in humans [134]. Several paediatric/obstetric anaesthetics and anticonvulsants
reduce NMDAR activity directly or indirectly; in addition, in utero exposure to NMDAR-
antagonistic recreational drugs such as phencyclidine, ketamine and ethanol pose significant
risks [134]. A greater knowledge of the mechanism of NMDAR-dependent neuroprotection
not only increases our understanding of this important pro-survival pathway, but also points
to ways in which it might be mimicked for therapeutic effect (for example to mitigate
against the harmful effects of NMDAR antagonists).
In the mature CNS, and despite evidence from animal studies implicating the NMDAR in
ischemic brain damage, clinical trials of NMDAR antagonists for stroke have failed due to
poor tolerance and efficacy [15, 18]. The important role of NMDARs in the CNS may mean
that for any antagonist, the maximal tolerated dose is lower than the therapeutically effective
dose, since many unacceptable side-effects are on-target effects. Evidence that NMDAR
activity can exert a neuroprotective effect has led to suggestions that it may even promote
recovery post-reperfusion, and prevent delayed neuronal loss in the penumbra [15, 19]. As
such, antagonists may be protective early in the insult but not later on, which indicates a
potential need for more specific anti-excitotoxic strategies where the effects on pro-survival
NMDAR signalling are considered. One promising strategy is the use of antagonists which
preferentially block excitotoxic NMDARs in excitotoxic scenarios, or which are activated
only in the pathological state (so-called pathologically activated therapeutics [135]). As an
example of the former, memantine is a clinically well-tolerated NMDAR antagonist with
pharmacological properties suited to the blockade of chronic NMDAR activity in
pathological scenarios without interfering with normal synaptic function [135].
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As described in this review, another approach involves targetting a site of action
downstream of NMDAR activation, several of which have been described above. For
example, peptide-mediated inhibition of JNK, of STEP cleavage, of mGluRα cleavage and
of NR2 PDZ interactions have all been shown to have neuroprotective effects in the face of
excitotoxic insults [7, 95, 96, 100]. The precise pathway, or pathways that mediate
NMDAR-dependent cell death in ischemia may depend on the neuronal subtype, the severity
and duration of the episode, and the position of the neuron within the lesion (infarct core or
penumbra). Thus, it may be that targeting JNK signalling or NO production may ameliorate
neuronal loss in some scenarios, but that blocking TRPM7 activation, or preventing the
cleavage of specific calpain targets is more effective in others. As such, the selective
targeting of multiple pro-death pathways downstream of the NMDARs may represent an
effective and well-tolerated therapeutic strategy.
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Fig. 1. Neuroprotective signalling by synaptic NMDAR activity
Some examples of anti-apoptotic and antioxidant signalling events that can promote
neuroprotection. See text for details.
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Fig. 2. Synaptic NMDAR activity boosts intrinsic antioxidant defences
A schematic showing impact of activity-dependent changes in gene expression on the
thioredoxin-peroxiredoxin cycle (events shaded in grey). Briefly, detoxification of peroxides
is mediated through the transfer of reducing equivalents from NADPH to peroxides via the
redox-active sulfhydryl (-SH) groups of thioredoxin and peroxiredoxins (Prx, the two-
cysteine peroxiredoxin major subtype is shown here). The redox active −SH group of Prx is
oxidized to −SOH by peroxides. Ordinarily this converts to a disulfide bond upon reaction
with the resolving cysteine −SH group, which is in turn reduced by thioredoxin, returning
Prx back to its reduced form. If levels of peroxide get to high or thioredoxin/peroxiredoxin
activity too low, the −SOH group becomes hyperoxidized to −SO2H (cysteine sulfinic acid)
which is not a substrate for the resolving cysteine or for thioredoxin. Instead, sulfiredoxin
(and possibly sestrin 2) catalyses the reduction of hyperoxidized Prx-SO2H and returns is to
the thioredoxin cycle. Synaptic activity triggers the events shown (and described in the text)
to both enhance thioredoxin activity and boost the reduction of hyperoxidized Prxs.
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Fig. 3. Neurodestructive signalling by NMDAR activity
Some examples of excitotoxic signalling events promoted by NMDAR activity. Note that
some of these events, such as CREB inactivation, calpain-mediated STEP cleavage and
disruption of mitochondrial membrane potential are preferentially triggered by chronic
extrasynaptic NMDAR activation, rather than trans-synaptic activation of synaptic
NMDARs. See text for details.
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